(RTTNews) - Intensity Therapeutics, Inc. (INTS), a late-stage clinical biotechnology company focused on immune-based cancer therapies, announced Tuesday that its INVINCIBLE-3 Study has been authorized to continue without modification by the Data Monitoring Committee or DMC.
This decision follows the DMC's periodic review of the data from the Phase 3 trial of INT230-6, which is being investigated as a treatment for soft tissue sarcoma.
The DMC's review of the data from July to December 2024 has confirmed that there are no safety concerns and the study can proceed as planned.
This pivotal study is testing INT230-6, an intratumoral therapy, against standard chemotherapy in patients with locally recurrent, inoperable, or metastatic soft tissue sarcoma, including leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma.
The trial, which is ongoing in the U.S., Canada, Europe, and Australia, aims to evaluate the overall survival and safety of INT230-6.
This treatment has shown promise in prior clinical studies, demonstrating its ability to kill tumors and trigger an immune response, all without the need for immunosuppressive chemotherapy.
Intensity Therapeutics is optimistic about the future of INT230-6 as it continues to enroll patients in this important study, aiming to provide an innovative treatment option for patients with limited therapeutic choices in this challenging disease area.
Currently, INTS is trading at $2.27 down by 2.54%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
